November 2, 2026
A new name to reflect a broader scope, building on decades of clinical research
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) today announced that its team supporting the Navy’s Austere Environments Consortium for Enhanced Sepsis Outcomes (ACESO) program has refined its mission and will officially become Accelerating Translational Research Solutions in Severe Infection (ATLAS), effective November 2, 2026.
This progression marks an exciting evolution of the HJF-ACESO team’s focus from developing host-based solutions specifically addressing sepsis to the full spectrum of trauma and severe infections. As ATLAS, the team will remain dedicated to developing solutions at the point-of-need for warfighters and civilians in resource-limited environments and build upon a robust foundation of clinical research driven by HJF in support of ACESO since 2011.
ATLAS will work with partners from government, academia and industry to elevate and advance biomedical research that elucidates solutions against the maladaptive immune response that results from trauma, infectious diseases or sepsis. In these endeavors, ATLAS will advance scientific knowledge, develop innovative approaches to disease diagnosis and prognoses, ultimately translating findings from research to clinical testing of applications that improve patient outcomes.
“ATLAS drives the advancement of host-directed solutions for critical infections across the development life cycle. From discovery to clinical evaluation, we generate the real-world evidence that moves diagnostics, therapeutics, and countermeasures from innovation to deployment.”
~ Carlyle Gollogly, Director
Why the Change:
Since the Navy launched ACESO in 2010 as a consortium of government, academic, industry, and non-profit partners including HJF, ACESO enrolled 5,692 patients, published 49 studies, and built 75 partnerships. Over time, the work of the HJF-ACESO team has expanded to address broader challenges that contribute to the global burden of sepsis to include other severe infections, combat trauma, and access to sustainable solutions. The ATLAS name reflects the HJF team’s widening scope with sharper focus on solutions, speeding the path from scientific discovery to clinical impact.
Looking to understand host biology and use insights gained to outpace complex infections, ATLAS bridges the gap between challenges in clinical treatment and precision medicine. We combine unprecedented access to high-acuity global patient networks and expertly curated data with advanced ML-driven multi-omics and field-ready companion diagnostics, to de-risk pipelines, validate host-directed mechanisms, and accelerate life-saving products to market faster.
What Stays the Same:
As ATLAS, the HJF team will continue the work, leadership, and scientific standards it contributed to ACESO. Existing studies, partnerships, funding agreements, and collaborations will continue without interruption, and no action is required from partners or funders. ATLAS will provide valuable scientific expertise and evidence-based insights via:
- A world-class research and development platform to understand and develop solutions for the dysregulated host-response in sepsis and severe infections.
- A broad CONUS and OCONUS Clinical Research Network positioned in key sites to surveil and mitigate biothreats of significant consequence.
- Adaptive Master Protocols to enable agile and timely response to emerging needs.
- A pipeline for supporting accelerated advancement of technologies and therapies through the life cycle of development from innovation to deployment.
- Expansive in-house clinical, translational biology, computational, logistics, program management and military relevant expertise.
What's New:
- A renewed commitment to transform the global standard of care for severe infections and sepsis by uniting advanced systems biology, multi-omic discovery, resilient clinical networks, scalable applications, and real-time clinical intelligence.
- A new name, logo, and visual identity
- An updated website at https://www.hjf.org/atlas
- A new LinkedIn page at https://www.linkedin.com/showcase/hjf-atlas
For more information contact Carlyle Gollogly, Director, ATLAS.